Liothyronine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Liothyronine: Renal hypodysplasia/aplasia
One-Sentence Summary
Liothyronine (synthetic triiodothyronine, T3) is a thyroid hormone replacement originally used for hypothyroidism and related thyroid conditions such as goitre. The TxGNN model predicts it may be effective for renal hypodysplasia/aplasia, but there are 0 clinical trials and 0 publications supporting this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Renal hypodysplasia/aplasia |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Liothyronine is the active form of thyroid hormone, and its efficacy in replacing thyroid hormone in hypothyroidism is well established. However, the data compiled for this report do not support a mechanistic link to renal hypodysplasia/aplasia.
Renal hypodysplasia/aplasia is a congenital structural disorder of kidney development that arises during embryogenesis. Giving thyroid hormone after birth is unlikely to reverse missing or underdeveloped kidney tissue. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or true therapeutic efficacy.
The other top-ranked predictions show the same pattern. Bilateral renal agenesis, Potter sequence, Carney complex, angiomyxoma, myxoma and peripheral dysostosis all have no clinical trials, and the ones with no publications have no supporting literature either. Nodular goitre is biologically plausible but is largely an existing use rather than true repurposing. Treat these predictions as hypotheses only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for renal hypodysplasia/aplasia.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13966C | Tertroxin | Tablet containing liothyronine sodium 20 micrograms (oral) | Not stated in the data compiled for this report |
Safety Considerations
Contraindications flagged by the knowledge graph (these come from drug-disease relationships in the model’s knowledge graph, not from approved label text, and should be verified against the Product Information). Conditions flagged include:
- Cardiovascular: hypertension, coronary artery disease, myocardial infarction
- Endocrine: pituitary hormone deficiencies (hypopituitarism and related forms), hypogonadotropic hypogonadism and Kallmann syndrome, Sheehan syndrome
- Metabolic: diabetes mellitus, diabetic ketoacidosis
- Bone: osteoporosis, including postmenopausal osteoporosis
- Other: thymus gland disease
Drug Interactions: The interaction screening returned 100 interactions in total. The 20 listed all have Moderate severity:
- Antidiabetic agents: acarbose, metformin, pioglitazone, alogliptin, linagliptin, canagliflozin, dapagliflozin, empagliflozin, albiglutide, dulaglutide, chlorpropamide
- Acid suppressants: omeprazole, rabeprazole, dexlansoprazole
- Minerals and antacids: calcium phosphate, calcium acetate, magnesium oxide
- Sympathomimetics: epinephrine, isometheptene, diethylpropion
Thyroid hormone can change glucose control, so patients taking antidiabetic drugs need closer monitoring. Calcium, magnesium and acid-suppressing drugs may reduce absorption of oral thyroid hormone.
Product Information warnings and contraindications for the Australian product were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for renal hypodysplasia/aplasia is supported only by a TxGNN model (deep learning) score (Evidence Level L5). There are no trials or publications, and a structural congenital kidney malformation is not plausibly treatable with thyroid hormone replacement.
To proceed, the following is needed:
- A documented mechanism of action and a plausible biological pathway linking thyroid hormone to renal development
- Preclinical or clinical evidence specific to renal hypodysplasia/aplasia
- Review of the Australian Product Information for warnings and contraindications
- Consideration of other predictions with a more plausible rationale (for example nodular goitre, which is largely an existing indication)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.